Clinical Study Of a Micro-Implantable Pulse Generator For The Treatment of Peripheral Neuropathic Pain (COMFORT 2)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 185
- 试验地点
- 17
- 主要终点
- Effectiveness: Responder Rates between the 2 groups
研究概览
简要总结
This post market study is being conducted to document the comparative effectiveness and safety of peripheral nerve stimulation plus conventional medical management versus conventional medical management alone in the treatment of chronic, intractable peripheral neuralgia of post-traumatic or postsurgical origin. This is a prospective, minimal risk, multi-center, randomized control trial.
详细描述
Multi-center, prospective, open-label, randomized controlled trial (RCT) comparing PNS plus CMM with CMM alone. Subjects will be randomized to receive:
Arm 1: Nalu Neurostimulation System for PNS plus CMM Arm 2: CMM alone Consented subjects will receive a baseline evaluation and then be randomized 2:1 into one of two arms: 1) PNS+CMM arm or 2) CMM arm. Subjects assigned to Arm 1 will undergo a trial implant period using best clinical practices. Those subjects who pass the trial implant will receive the permanent implant. At the 3-month end point, subjects in Arm 2 will be given the option to crossover into Arm 1 beginning with a trial implant. All Arm 1 patients receiving a permanent implant will be followed for a total of 36 months after permanent implantation.Arm 2 patients who do not crossover will be followed for a total of 36 months from randomization.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is between 18 to 80 years of age at the time of enrollment.
- •Subject would have been prescribed PNS therapy regardless of participation in this study; the use of the Nalu device must be on-label.
- •Subject has been diagnosed with one or more of the conditions listed below in the low back, shoulder, knee, or foot (including ankle):
- •Post-surgical/post-traumatic peripheral neuralgia including but not limited to pain due to peripheral nerve injury, post-surgical scar formation, nerve entrapment
- •Mononeuropathy, specified or unspecified or in diseases classified elsewhere
- •Other neuralgia or neuropathic pain
- •Osteoarthritic pain
- •Subject has chronic (defined as at least 6 months duration), intractable peripheral neuropathic pain, exclusive of the craniofacial region; any nociceptive pain must be less prominent than the neuropathic pain. Pain should have a predominant neuropathic component as per the investigator's clinical assessment.
- •Subject should have a pain score of at least 6, in the target area of pain, as recorded on the BPI-Q5 (NRS) at screening.
- •Subject is willing to cooperate with the study requirements including, compliance with the study procedures and completion of all study visits.
- •Subject reported stable pain (non-escalating) for 60 days prior to signing informed consent.
- •Subject is currently receiving CMM and has had stable pain medication use and dosage for 30 days prior to signing informed consent.
- •Subject is psychologically qualified to receive a peripheral nerve stimulator as per the clinician's standard clinical practice and judgment and does not have clinically relevant psychological condition(s) that would interfere with their ability to accurately report outcomes or complete study procedures.
- •Subject has demonstrated the ability to appropriately place the adhesive clip in the location where the IPG is most likely to be implanted. Alternatively, subject is able to appropriately use the relief belt and/or limb cuff to keep the Therapy Disc in place.
排除标准
- •Subject currently has an active implantable medical device such as a drug pump, spinal cord stimulator, peripheral nerve stimulator, sacral nerve stimulator, deep brain stimulator, and/or cardiac pacemaker.
- •2. Subject has previously failed PNS or Spinal Cord Stimulation (SCS) or Dorsal Root Ganglion (DRG) therapy (trial or permanent implant). See note below.
- •3. Pain is completely absent at rest.
- •Patient has clinical evidence of complex regional pain syndrome (CRPS), peripheral neuralgia of metabolic origin, post-herpetic neuralgia, biochemical evidence of a metabolic or genetic neuropathy (e.g., Charcot'- Marie- Tooth Disease) or mixed motor/sensory polyneuropathy.
- •5. Subject has a medical condition that would prevent them from participating in the current study per investigator's or medical monitor's judgment.
- •6. Subject has had a successful (≥ 50% pain relief) interventional procedure within the past 3 months to treat the same pain condition(s) being examined in this study including, nerve blocks.
- •7. Uncontrolled depression or uncontrolled psychiatric disorders
- •Subject is currently participating in another clinical investigation with an active treatment arm.
- •9. Subject is allergic or sensitive to materials used in the device components including, skin adhesives or does not tolerate the wearable aspect of the device.
- •10. Subject has pending or ongoing legal issues (including unresolved worker's compensation claims or equivalent) or other conflicting secondary gain issues related to their chronic pain condition.
- •11. Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, or progressive peripheral vascular disease that has not been medically corrected.
- •12. Subject has an active systemic infection.
- •Subject is unable to read and/or write in English or give informed consent.
- •Subject has a life expectancy of less than 1 year.
- •Subject has an active malignant neoplasm (metastatic or local) or evidence of paraneoplastic syndrome.
- •16. Subject with uncontrolled diabetes mellitus, showing signs of diabetic neuropathy, as evidenced by a neurological exam and a HbA1c test.
- •17. Subject has evidence of an alcohol or drug dependency within the last 6 months prior to enrollment.
- •18. Subject is pregnant (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile or be at least 1 year post-menopausal).
- •19. Subject is nursing/breastfeeding.
- •Subject is on ≥90 mg-morphine equivalents per 24 hours.
- •Subject has undergone an ablative treatment of the target peripheral nerve, or proximal nerve trunk giving rise to the target nerve, or dorsal roots (and DRGs) that ultimately make up the target nerve. No ablative procedures directed at the spinal cord, dorsal roots, or peripheral nerve(s) being treated in the study. To note, subjects who have undergone RF ablation of the dorsal rami, cool pulsed RF of the facet innervation may be considered for enrollment.
研究组 & 干预措施
PNS Therapy plus Conventional Medical Management (CMM)
Subjects in this arm will receive a peripheral nerve stimulator and conventional medical management
干预措施: Nalu Neurostimulation System for PNS (Device)
PNS Therapy plus Conventional Medical Management (CMM)
Subjects in this arm will receive a peripheral nerve stimulator and conventional medical management
干预措施: Conventional Medical Management (Other)
Conventional Medical Management
Subjects will receive only CMM
干预措施: Conventional Medical Management (Other)
结局指标
主要结局
Effectiveness: Responder Rates between the 2 groups
时间窗: 3-months
Difference in responder rates between groups. Responder rate is defined as the percent of subjects with 50% or greater pain relief from baseline, based on the Numeric Rating Scale (0-10; 0=no pain, 10=worst pain imaginable)
Safety: Rate of serious and non-serious device effects
时间窗: 3-months
Rate of serious and non-serious adverse device events between groups
次要结局
- Responder Rates(6-months,12 months, 24 months and 36-months)
- Functional Outcomes: Change in Oswestry Disability Index (ODI) score from baseline to protocol defined timepoints(3 months, 6-months,12 months, 24 months and 36-months)
- Functional Outcomes: Change in Beck's Depression Inventory (BDI) score from baseline(3 months, 6-months,12 months, 24 months and 36-months)
- Functional Outcomes: Patient Global Impression of Change (PGIC)(3 months, 6-months,12 months, 24 months and 36-months)
- Safety Assessment(6-months,12 months, 24 months and 36-months)